Media coverage about Medivation (NASDAQ:MDVN) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Medivation earned a news impact score of 0.22 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 47.4451860957354 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Medivation (NASDAQ MDVN) traded up $0.04 during trading hours on Tuesday, reaching $81.48. 8,577 shares of the company traded hands, compared to its average volume of 3,545,656. The company has a market capitalization of $13,520.00, a PE ratio of -69.64 and a beta of 0.60. Medivation has a twelve month low of $26.41 and a twelve month high of $81.48. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 0.03.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright law. The original version of this report can be viewed at

Medivation Company Profile

Medivation, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI).

Insider Buying and Selling by Quarter for Medivation (NASDAQ:MDVN)

Receive News & Ratings for Medivation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medivation and related companies with Analyst Ratings Network's FREE daily email newsletter.